<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ890918-0081 </DOCNO><DD> = 890918 </DD><AN> 890918-0081. </AN><HL> Who's News:@  Bio-Technology Picks@  Illick for Firm's Board </HL><DD> 09/18/89 </DD><SO> WALL STREET JOURNAL (J) </SO><CO> WNEWS </CO><DATELINE> NEW YORK  </DATELINE><TEXT>   Bio-Technology General Corp., a health-care products concern, named Christopher Illick to its five-member board.    Mr. Illick, general counsel and corporate secretary of Clarendon America Insurance Co., fills the seat vacated by Frederick R. Adler. Mr. Adler, who resigned, is a venture capitalist who controls 13.4% of Bio-Technology common.    The company said it is waiting to hear from the Securities and Exchange Commission about Bio-Technology's plan for debt restructuring. Major holders have approved the plan. Without such a restructuring or additional financing, the company faced the prospect of a bankruptcy-law filing. </TEXT></DOC>